ScreenerHero

ARGXargenx SE

NAS · US · Healthcare · Biotechnology · argenx.com
1039.78USDMkt Cap: 65.05B $P/E: 39.55

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART fo…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
CORT
Corcept Therapeutics Incorporated
$13.22BUSDP/E 271.7
BMRN
BioMarin Pharmaceutical Inc.
$12.91BUSDP/E 180.3

Key Statistics

Company
Market Cap65.05B $
Enterprise Value1.62T $
Revenue (TTM)5.32B $
Gross Profit3.70B $
Net Income (TTM)1.29B $
Revenue/Share3.436 USD
Last Price1039.78 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.9K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINNL0010832176
Valuation
P/E (Trailing)39.55
P/E (Forward)26.53
PEG1.63
EV/EBITDA1004.71
EV/Revenue304.87
P/S12.16
P/B193.14
EPS (TTM)26.20
EPS (Forward)39.20
52W Range
1029.4635% of range1058.69
52W High1058.69 USD
52W Low1029.46 USD
Profitability
Gross Margin89.15%
Oper. Margin31.99%
EBITDA Margin30.34%
Profit Margin31.11%
ROE17.64%
ROA14.88%
Growth
Revenue Growth59.30%
Earnings Growth95.20%
Cash Flow & Leverage
Operating CF685.19M $
CapEx (TTM)111.68M $
FCF Margin14.33%
FCF Yield1.17%
Net Debt-5.14B $
Net Debt/EBITDA-3.18
Balance Sheet
Debt/Equity0.01
Current Ratio5.12
Quick Ratio4.52
Book Value/Sh5.384 USD
Cash/Share3.316 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1172.78 USD
Upside (mean)+12.8%
Target Range900.00 USD – 1450.00 USD
$900.00+12.8% to mean$1450.00
# Analysts23
Ownership
Shares Out.62.56M
Float1.56B
Insiders0.00%
Institutions46.20%
Short Interest
Short Ratio4.4d
Short % Float2.13%
Short % Out.2.13%
Shares Short1.33M
Short (prev mo.)1.45M
Technical
SMA 50894.64 (+16.2%)
SMA 200836.54 (+24.3%)
Beta-0.04
S&P 52W Chg19.18%
Avg Vol (30d)301.27K
Avg Vol (10d)350.48K
Technical Indicators
RSI (14)73.5
MACD36.8848
MACD Signal16.1114
MACD Hist.+20.7735
BB Upper1044.03 USD
BB Middle903.01 USD
BB Lower761.99 USD
BB Width31.23%
ATR (14)33.86 USD
Vol Ratio (20d)0.98x